Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.55 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978357 | 1.00 | NR3C1 (0.61) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL4826656 | 0.87 | NR3C1 (0.64) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL8242650 | 0.87 | NR3C1 (0.64) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL14571254 | 0.87 | NR3C1 (0.64) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL6705112 | 0.86 | NR3C1 (0.47) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL6839221 | 0.85 | PGR (0.51) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL4255035 | 0.84 | NR3C1 (0.44) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL4818856 | 0.83 | NR3C1 (0.43) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL4818843 | 0.83 | NR3C1 (0.43) | NR3C1CYP19A1ARPGRNR3C2 | |
| SCHEMBL11313578 | 0.83 | NR3C1 (0.72) | NR3C1CYP19A1ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S | 2008-01-31 | — | — | US | disclosed |
| US-6887991-B1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G. D. SEARLE & COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-6610844-B2 | Removing an 11-alpha-leaving group from an epoxymexrenone derivative | G.D. SEARLE & COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030055274-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | G.D. SEARLE & COMPANY | 2003-03-20 | — | — | US | disclosed |
| EP-0944644-B1 | PROCESSES FOR PREPARATION OF 3-KETO-7alpha-ALKOXYCARBONYL-delta-4,5- STEROIDS AND INTERMEDIATES USEFUL THEREIN | SEARLE & CO (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1223174-A2 | Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1148061-A2 | Process for preparation of 9, 11- epoxy steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2001-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027237-A1 | Processes for preparations of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, CYP11B1, CYP17A1 | NR3C1 89/4885CYP19A1 14/4885AR 169/4885 |
| US-20030055274-A1 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | NR3C1 45/4885CYP19A1 152/4885AR 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.